ZCI
SAGE

Zevenbergen Capital Investments’s Sage Therapeutics SAGE Stock Holding History

Zevenbergen Capital Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-236,587
Closed -$17.1M – 84
2019
Q4 		$17.1M Buy
236,587
+143,306
+154% +$17.6M 0.63% 31
2019
Q3 		$13.1M Buy
+93,281
New +$15.6M 0.5% 35

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Zevenbergen Capital Investments's SAGE Position: Q1 2020 in Review

Zevenbergen Capital Investments sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 236,587 shares — an estimated $17.1M sold.

Zevenbergen Capital Investments first reported a position in SAGE in Q3 2019 and held it in 2 quarters. The position peaked at $17.1M in Q4 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Zevenbergen Capital Investments reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 236,587 Sage Therapeutics shares in Q1 2020, an estimated $17.1M.
  • Zevenbergen Capital Investments first reported a position in Sage Therapeutics in Q3 2019 and held it in 2 quarters.
  • Zevenbergen Capital Investments's Sage Therapeutics position peaked at $17.1M in Q4 2019.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Zevenbergen Capital Investments's 13F filing for Q1 2020, filed 12 May 2020.